EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy and side effects of anti‐CD19 CAR T‐cell therapy in patients with relapsed/refractory gastrointestinal lymphoma

Yi Li Jiang iD, Juan Mu, Rui Cui, Xin Li, Jia Wang, Qing Li iD, Jingyi Li, Nan Mou, Qi Deng iD

Cancer Medicine · 2024

DOI: 10.1002/cam4.7064 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Yi Li Jiang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China. Hauptthemen laut MEDLINE: Lymphoma, Lymphoma, B-Cell, Gastrointestinal Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chinese Society of Clinical Oncology Beijing Xisike Clinical Oncology Research Foundation, Tianjin Health Research Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Although anti‐CD19 chimeric antigen receptor (CAR) T cell therapy was approved as a very effective salvage strategy in relapsed/refractory (R/R) B cell lymphoma, the experience in R/R gastrointestinal (GI) lymphoma is still insufficient.

Methods

We summarized the efficacy and side effects of anti‐CD19 CAR T‐cell therapy in 12 patients with R/R GI lymphoma. Based on literature, the R/R GI lymphoma patients were divided into subgroups with different characteristics: Bulky/No bulky disease, Gastric/Gastrointestinal involvement, Gastrointestinal/Combined extra‐gastrointestinal lesions, Ulcer/Lumps or nodules type, With/without gastrointestinal bleeding.

Results

The objective response rate (ORR) was 66.67% in these 12 patients. The ORR was 83.33% in no bulky disease group, 80.00% in gastric involvement group, 100.00% in ulcer type group, and 80.00% in no gastrointestinal bleeding group. The CR rate was 33.33% in these 12 patients. The CR was 50.0% in no bulky disease group, 60.00% in gastric involvement group, and 80.00% in ulcer type group. The PFS and OS rate of the 12 patients at 6 months after infusion were 54.55% and 58.33%, respectively. The overall survival (OS) at 6 months was higher in no bulky disease group. There was no difference of the OS or the progression free survival (PFS) at 6 months between the other groups. The mean peak of CAR‐T cells and Cytokine Release Syndrome (CRS) grade were higher in gastrointestinal lesions group. The mean peak of IFN‐γ and CRS grade were higher in gastrointestinal bleeding group. Four out of six patients in group of gastrointestinal lesions group were patient with high tumor burden. Patients with gastrointestinal involvement only were at higher risk for gastrointestinal bleeding.

Conclusions

The ORR and CR of high tumor load, gastrointestinal involvement, lumps or nodules type and gastrointestinal bleeding group were lower. The CRS grade was higher in gastrointestinal lesions group and in gastrointestinal bleeding group. Patients with gastrointestinal involvement only were at higher risk for gastrointestinal bleeding.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LymphomaLymphoma, B-CellGastrointestinal NeoplasmsHumansImmunotherapy, AdoptiveReceptors, Antigen, T-CellT-LymphocytesUlcerCytokine Release SyndromeAntigens, CD19Gastrointestinal Hemorrhage

Stichwörter der Autor:innen

B-cell lymphomachimeric antigen receptor (CAR)gastrointestinal lymphomarelapsed/refractory

Substanzen

Receptors, Antigen, T-CellAntigens, CD19

Autor:innen und Institutionen

  • Department of Hematology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China.
  • Shanghai Genbase Biotechnology Co., Ltd, Shanghai, China.

ORCID-Profile: Yi Li Jiang, Qing Li, Qi Deng

Förderung

  • Chinese Society of Clinical Oncology Beijing Xisike Clinical Oncology Research Foundation
  • Tianjin Health Research Project

Zitieren

APA

Jiang, Y. L., Mu, J., Cui, R., Li, X., Wang, J., Li, Q., Li, J., Mou, N., & Deng, Q. (2024). Efficacy and side effects of anti‐CD19 CAR T‐cell therapy in patients with relapsed/refractory gastrointestinal lymphoma. Cancer Medicine. https://doi.org/10.1002/cam4.7064

Vancouver

Jiang YL, Mu J, Cui R, Li X, Wang J, Li Q, et al. Efficacy and side effects of anti‐CD19 CAR T‐cell therapy in patients with relapsed/refractory gastrointestinal lymphoma. Cancer Medicine. 2024. doi:10.1002/cam4.7064

BibTeX
@article{Jiang2024,
  author = {Jiang, Yi Li and Mu, Juan and Cui, Rui and Li, Xin and Wang, Jia and Li, Qing and Li, Jingyi and Mou, Nan and Deng, Qi},
  title = {Efficacy and side effects of anti‐CD19 CAR T‐cell therapy in patients with relapsed/refractory gastrointestinal lymphoma},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.7064}
}
Kostenlos starten →